Literature DB >> 6136990

Agonistic action of a benzodiazepine antagonist: effects of Ro 15-1788 and midazolam on hypertonic NaCl intake.

M Tang, S Soroka, J L Falk.   

Abstract

Rats adapted to a 23-hr water deprivation regimen were allowed a daily 1-hr water rehydration session. On test days the session drinking fluid was 1.5% NaCl solution rather than water. One group was injected (SC) with the benzodiazepine antagonist Ro 15-1788 (2.5-10 mg/kg) and another group with the agonist agent midazolam (0.13-2.0 mg/kg) every 5-6 days at 10 and 15 min before a test session, respectively. Both Ro 15-1788 and midazolam increased 1.5% NaCl solution intake in a dose-related manner. In this study and in previous research, benzodiazepines and barbiturates were shown to increase the intake of hypertonic NaCl solutions. The present results reveal a similar effect for Ro 15-1788, indicating an agonistic dimension to the spectrum of action of this specific receptor antagonist.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6136990     DOI: 10.1016/s0091-3057(83)80020-3

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  4 in total

1.  Benzodiazepine receptor ligands and the consumption of a highly palatable diet in non-deprived male rats.

Authors:  S J Cooper; D J Barber; D B Gilbert; W R Moores
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

Review 2.  Intrinsic actions of the benzodiazepine receptor antagonist Ro 15-1788.

Authors:  S E File; S Pellow
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

3.  Selective reduction by serotonergic agents of hypertonic saline consumption in rats: evidence for possible 5-HT1C receptor mediation.

Authors:  J C Neill; S J Cooper
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

4.  Dose-dependent reversal of chlordiazepoxide-induced discrimination impairment by Ro 15-1788.

Authors:  S O Cole
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.